[go: up one dir, main page]

WO2006031142A1 - Matiere biologiquement active, procede de production de celle-ci et agent therapeutique obtenu a partir de celle-ci - Google Patents

Matiere biologiquement active, procede de production de celle-ci et agent therapeutique obtenu a partir de celle-ci Download PDF

Info

Publication number
WO2006031142A1
WO2006031142A1 PCT/RU2005/000133 RU2005000133W WO2006031142A1 WO 2006031142 A1 WO2006031142 A1 WO 2006031142A1 RU 2005000133 W RU2005000133 W RU 2005000133W WO 2006031142 A1 WO2006031142 A1 WO 2006031142A1
Authority
WO
WIPO (PCT)
Prior art keywords
carrier
therapeutic
purulent
treatment
polycaproamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2005/000133
Other languages
English (en)
Russian (ru)
Inventor
Vladimir Nikolaevich Filatov
Vladimir Valentinovich Ryltsev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DUSHAK ROSTISLAV MIKHAILOVICH
Original Assignee
DUSHAK ROSTISLAV MIKHAILOVICH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DUSHAK ROSTISLAV MIKHAILOVICH filed Critical DUSHAK ROSTISLAV MIKHAILOVICH
Priority to PCT/RU2005/000133 priority Critical patent/WO2006031142A1/fr
Publication of WO2006031142A1 publication Critical patent/WO2006031142A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/38—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/43—Hormones, e.g. dexamethasone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures

Definitions

  • the present invention relates to medicine, specifically to a material (system) having biological activity, a method for its preparation and a therapeutic agent based on the specified material (system) in the form of wound coverings, which are intended for the treatment of purulent-necrotic wounds, trophic ulcers and other similar diseases.
  • a known method for producing material (DE 197 47 832 Al) in the form of a wound cover for use in the treatment of purulent-necrotic wounds, etc. damage.
  • the method consists in the fact that cotton fabric in the form of medical gauze is pre-oxidized with a sodium periodate solution to a DAC containing aldehyde groups of 0.04-0.06 mEq. On 1 g of the carrier. Then, the material is treated with a mixture of trypsin and insulin solutions with a bath module of 2.5.
  • the bath module is the ratio of the weight of the solution to the weight of the processed material.
  • the aldehyde groups of the carrier material interact with the free amino groups of trypsin and insulin to form an azomethine bond and, as a result, these proteins are immobilized on the material.
  • the referenced link states that when a polycaproamide knit fabric is used as a carrier, aldehyde groups are introduced by treating the polycaproamide knit fabric with glutaraldehyde. The final product contains trypsin, trypsin and insulin as the active ingredient.
  • RU 2 142 818 discloses a method for producing dressings comprising treating an activated textile carrier material with a protein preparation solution, followed by keeping the treated carrier material in air and drying.
  • dialdehyde cellulose or polycaproamide with an aldehyde group content of 0.04-0.06 mEq are used as activated textile material. per 1 g of carrier, and the treatment is carried out by adding the activated textile material in a protein solution.
  • the material contains, as immobilized proteins, trypsin or trypsin and insulin or trypsin and lysozyme.
  • the link states that the use of material obtained by the disclosed method allows you to clean the wound within 2.2-2.6 days.
  • the present invention provides a novel therapeutic material for wound closure having biological activity capable of accelerating wound cleansing and healing.
  • the first aspect of the present invention is a therapeutic material based on a textile carrier, which is used cotton fabric made from dialdehyde dellulose (DAC) or polycaproamide knitted fabric.
  • DAC dialdehyde dellulose
  • This therapeutic material is intended for the treatment of purulent-necrotic wounds of various origins.
  • Such wounds can be trophic wounds in patients with diabetes mellitus.
  • a distinctive feature of the claimed material is that, unlike the prior art, it contains three immobilized proteins as active ingredients, one of which is a hormone.
  • Such proteins are proteolytic enzymes (trypsin, chymotrypsin, terrilithin, etc.), bacteriolytic enzymes (lysozyme, lysoamidase) and hormones (insulin from the pancreas of humans, bovines, pigs, recombinant insulin).
  • Trypsin, lysozyme and insulin are present in the weight ratio of 1: 1.33: 1.67, respectively, per 1 g of carrier.
  • the therapeutic material according to this aspect of the invention is characterized in that the content of aldehyde groups in the activated carrier material is at least 0.02, for example, 0.08-0.10 mEq. per 1 g of carrier, which significantly exceeds the number of active groups necessary for complete protein binding and ensures their immobilization in the ratio in which they are in the initial solution.
  • the therapeutic material based on a polycaproamide knitted fabric or dialdehyde cellulose in accordance with the present invention is an application that is used in the treatment of extensive, shallow wounds.
  • the therapeutic material based on dialdehyde cellulose in accordance with this aspect of the invention can be subjected to mechanical destruction on available equipment to the state of lint (cotton wool).
  • the corporation is more profitable and more convenient than application in the treatment of narrow and deep pathological foci (bullet, mine-fragmentation and puncture wounds, gingival pockets, ulcerative niches).
  • a therapeutic material based on dialdehyde cellulose can be crushed to a powder state with particle sizes of 0.1-0.6 mm.
  • the specified powder with a particle size of 0.5-0.6 mm can be introduced into the ear canal using an insufflator for the treatment of external otitis media.
  • the same powder with a particle size of 0.3-0.4 mm can be introduced into the composition of gels, ointments, suppositories, etc. on a hydrophilic basis.
  • the same powder with a particle size of 0.1-0.2 mm can be introduced into the volume of an aerosol can containing components that form foam when applied to the surface of the wound.
  • the technology of Altivitamins ( Russian) can be used.
  • a further aspect of the invention is a therapeutic agent based on the therapeutic material of the first aspect of the present invention.
  • the therapeutic agent in accordance with the present invention comprises, in addition to the treatment layer, which is a therapeutic material based on a textile carrier - dialdehyde cellulose cotton fabric or polycaproamide knitted fabric in accordance with the first aspect of the invention, further other layers, one of which is a drainage layer that absorbs wound exudate. As a rule, this is a hydrophilic material. It is possible to use an additional outdoor a layer that protects the wound from dirt, dust, pathogens and drying out.
  • the present invention relates to a method for producing a therapeutic material in accordance with a first aspect of the invention.
  • the method includes the following stages: activation of the textile carrier to the content of aldehyde groups of 0.08-0.10 mEq. Per gram of carrier; immobilization on an activated carrier of three biologically active components of protein nature, taken in an effective amount for the rapid cleansing and healing of purulent necrotic wounds.
  • a cotton fabric made of cellulose or a knitted fabric of polycaproamide is used as a textile carrier.
  • Activation is carried out by known methods, for example, by treating a cotton cellulose fabric with sodium periodate to cellulose dildehyde or by treating a polycapramide web with glutaraldehyde.
  • trypsin, lysozyme and insulin are used to immobilize.
  • the number of immobilized molecules are in a weight ratio of 1: 1.33: 1.67, respectively.
  • the invention is further illustrated by examples of its implementation and comparative examples illustrating the advantages.
  • a solution is prepared containing 0.55 g of lysozyme and b, b l of water.
  • the previously obtained DAC is dipped into it for 2 hours, then the DAC is squeezed out and placed for 2 hours in 6.6 L of water containing 0.44 g of insulin.
  • DAC is again squeezed out and placed for 2 hours in 6.6 L of water containing 0.33 g of trypsin.
  • DAC is again squeezed and dried in air to a residual moisture content of not more than 10%. Residual moisture is measured by the gravimetric method.
  • the material is dried at 105 degrees to constant weight, weight loss is expressed as a percentage.
  • the material is cut into workpieces of the required size, for example, 40x40 cm, and folded into a four-layer application with a size of 10x10 cm.
  • the carrier web obtained in Example 1 is folded in the form of 10x10 applications.
  • the resulting applications are combined with a drainage (absorbent) layer and covered with a protective layer, the layers are connected into a bandage by sewing.
  • the carrier web obtained in Example 1 is mechanically destroyed to the state of lint (cotton wool) and packaged in bags.
  • the carrier web obtained in Example 1 is milled to a powder with a particle size of 0.5-0.6 mm.
  • the powder is packaged in bottles with a rubber stopper and an aluminum cap.
  • the carrier web obtained in Example 1 is ground to a powder with a particle size of 0.1-0.2 mm and introduced into the foam composition of the forming mixture, which is filled with aerosol cans.
  • Example b The carrier web obtained in Example 1 is ground to a powder with a particle size of 0.3-0.4 mm, introduced into the gel composition on a hydrophilic basis and filled into tubes or formed using suppository powder.
  • a polycaproamide-based textile web is placed in 40 L of 3 M hydrochloric acid and kept for 4 hours at a temperature of 6O 0 C. The cloth is wrung out and washed with water until there are no chlorine ions in the wash water.
  • the web hydrolyzed in this way was incubated for 4 hours at 5O 0 C in 37.4 L of 10% glutaraldehyde.
  • An activated textile carrier is obtained, which is washed with water until the glutaraldehyde is completely odorless.
  • the carrier is dried in air to a residual moisture content of 10%.
  • the resulting carrier contains 0.08 mEq. aldehyde groups per 1 g of carrier.
  • this carrier is sequentially treated with solutions of lysozyme, insulin and trypsin according to the procedure described in example 1.
  • the carrier web obtained in example 7 is cut into applications of the required size, for example, 7.5x10, 10x10, 10x15, 15x20, 20x30cm, and packaged in plastic bags.
  • Packaged products in the form of applications, lint or powder are subjected to gamma radiation at a dose of 25 kGy.
  • Table 1 shows data demonstrating the effectiveness of therapeutic materials disclosed in patents and applications RU 2 062 113, RU 2 131 268, RU 2 142 818, DE 19747832 Al and US 6 500 799 B2, as well as demonstrated by the claimed therapeutic material.
  • Tab. l shows data demonstrating the effectiveness of therapeutic materials disclosed in patents and applications RU 2 062 113, RU 2 131 268, RU 2 142 818, DE 19747832 Al and US 6 500 799 B2, as well as demonstrated by the claimed therapeutic material.
  • proteolytic activity of a number of samples of therapeutic materials was studied.
  • DAC-based therapeutic material on which: lysozyme, insulin and trypsin were immobilized, (2) DAC-based therapeutic material on which insulin and trypsin were immobilized, and (3) DAC-based therapeutic material on which trypsin is immobilized.
  • proteolytic activity of therapeutic material (1) is 20% higher than that of material (2) and 30% higher than that of material (3).
  • Proteolytic activity was determined by a known method: Standard method for determining proteolytic activity for complex preparations of proteinases /. Kaverznova E. D. Applied Biochemistry and Microbiology. 1971. T.7. N ° 2. S. 225-229.
  • Atraumaticity can be estimated through the force of separation of the coating from the surface of the wound, which can be measured using a dynamometer, as described in the article: Method for a comparative assessment of the atraumaticity of dressings. Bychikhin N.P. and others // Surgery. 1986. JVk 66.S. 112-114.
  • the named advantage may be the result of higher humidity of the claimed therapeutic material. After air drying, the residual humidity of the medical gauze is about 4%, the material according to DE 19747832 Al is about 6%, and the therapeutic material according to the invention is about 8%.
  • lint or powder can be subjected to gamma radiation at a dose of 25 kGy. Such processing on the one hand allows you to form additional crosslinking with the carrier, and on the other hand, is sterilizing for the material.
  • Therapeutic materials containing three proteins immobilized on a polycaproamide carrier or based on DAC are preferably used as applications in the treatment of extensive, shallow wounds.
  • dressings can be made containing, along with the treatment, drainage, absorbent and moisture-retaining protective layers.
  • the mechanical strength of the therapeutic material based on DAC and therapeutic agents based on it is significantly lower than that of unmodified gauze. For this reason, therapeutic materials based on DAC can, if necessary, be crushed to the state of lint (cotton wool) or powder.
  • Therapeutic materials according to the claimed invention significantly reduce the healing time of purulent-necrotic wounds, and, therefore, accelerate their healing.
  • the therapeutic materials of the invention are distinguished substantially less traumatism, i.e., when removing material from the wound surface, less effort is required, which avoids additional trauma, eliminates bleeding that is common with other similar materials and thereby alleviate the patient's condition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne une matière thérapeutique et des agents thérapeutiques obtenus à partir de celle-ci servant au traitement de plaies pyonécrotiques, ainsi qu'un procédé de production de cette matière thérapeutique. La matière de cette invention comprend un support textile activé sur lequel de la trypsine, de l'insuline et de la lysozyme sont immobilisées. La matière thérapeutique de cette invention permet de réduire substantiellement le temps nécessaire au nettoyage de la surface d'une plaie et d'accélérer la cicatrisation de ladite plaie.
PCT/RU2005/000133 2005-03-24 2005-03-24 Matiere biologiquement active, procede de production de celle-ci et agent therapeutique obtenu a partir de celle-ci Ceased WO2006031142A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/RU2005/000133 WO2006031142A1 (fr) 2005-03-24 2005-03-24 Matiere biologiquement active, procede de production de celle-ci et agent therapeutique obtenu a partir de celle-ci

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2005/000133 WO2006031142A1 (fr) 2005-03-24 2005-03-24 Matiere biologiquement active, procede de production de celle-ci et agent therapeutique obtenu a partir de celle-ci

Publications (1)

Publication Number Publication Date
WO2006031142A1 true WO2006031142A1 (fr) 2006-03-23

Family

ID=36060301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2005/000133 Ceased WO2006031142A1 (fr) 2005-03-24 2005-03-24 Matiere biologiquement active, procede de production de celle-ci et agent therapeutique obtenu a partir de celle-ci

Country Status (1)

Country Link
WO (1) WO2006031142A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023286049A1 (fr) * 2021-07-12 2023-01-19 Zidkiyahu Simenhaus Compositions bioactives contenant des protéines et comprenant des supports de microparticules de cellulose

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2099095C1 (ru) * 1993-05-14 1997-12-20 Научно-производственная фирма "Нарт" Способ получения перевязочного материала для лечения рубцов
DE19747832A1 (de) * 1997-10-23 1999-04-29 Filatov Vladimir N Verfahren zur Herstellung eines Verbandmittels
RU2142818C1 (ru) * 1998-05-07 1999-12-20 Филатов Владимир Николаевич Способ получения перевязочных материалов "салфетки филатова-рыльцева"
US20020012692A1 (en) * 1999-04-09 2002-01-31 Filatov Vladimir N. Wound dressing

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2099095C1 (ru) * 1993-05-14 1997-12-20 Научно-производственная фирма "Нарт" Способ получения перевязочного материала для лечения рубцов
DE19747832A1 (de) * 1997-10-23 1999-04-29 Filatov Vladimir N Verfahren zur Herstellung eines Verbandmittels
RU2142818C1 (ru) * 1998-05-07 1999-12-20 Филатов Владимир Николаевич Способ получения перевязочных материалов "салфетки филатова-рыльцева"
US20020012692A1 (en) * 1999-04-09 2002-01-31 Filatov Vladimir N. Wound dressing

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023286049A1 (fr) * 2021-07-12 2023-01-19 Zidkiyahu Simenhaus Compositions bioactives contenant des protéines et comprenant des supports de microparticules de cellulose
US20240315972A1 (en) * 2021-07-12 2024-09-26 Zidkiyahu Simenhaus Protein containing bio-active compositions comprising cellulose microparticle carriers

Similar Documents

Publication Publication Date Title
EP1695722B1 (fr) Mousse hémostatique à base de collagéne
US4570629A (en) Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same
EP2939697B2 (fr) Éponge hémostatique
JP2003505156A (ja) 傷の治療を向上させる方法及び組成物
JP2008532662A (ja) 抗菌創傷包帯の作製方法およびその使用
JP6716841B2 (ja) 止血材
Thomas Hydrocolloids
US11938230B2 (en) Hemostatic material and wound dressing containing same
EP2916879B1 (fr) Dispositif de soins de plaie
EP1487506B1 (fr) Preparation favorisant la cicatrisation et empechant l'adhesion du pansement a la plaie
CS249311B1 (en) Proteolytic wound dressing
EP1299135B1 (fr) Pansement comprenant la terrilytin comme agent therapeutique actif
RU2108114C1 (ru) Биологическая композиция для лечения ран "коллахит"
RU2357753C1 (ru) Материал, обладающий биологической активностью, способ его получения и терапевтическое средство на его основе
JPS6330023B2 (fr)
CZ277766B6 (en) Biologically active material and process for preparing thereof
RU2240140C2 (ru) Медицинская многослойная повязка и изделия на ее основе
WO2006031142A1 (fr) Matiere biologiquement active, procede de production de celle-ci et agent therapeutique obtenu a partir de celle-ci
JPH04371161A (ja) キチン又はキトサンの綿状物
JPH10151184A (ja) 機能性創傷被覆材
RU2789304C1 (ru) Биоразлагаемая ранозаживляющая пленка
RU2323748C2 (ru) Медицинская повязка, содержащая комплекс ферментов из гепатопанкреаса краба, и способ ее получения
JPH03206032A (ja) 創傷被覆材
CN107224605A (zh) 一种高透气性烧烫伤敷料的制备方法
RU2462270C2 (ru) Способ получения повязки гидроколлоидной бактерицидной

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007139335

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 05792698

Country of ref document: EP

Kind code of ref document: A1